Recent advances in the development of Rho kinase inhibitors (2015-2021)

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Rho-associated coiled-coil kinases (ROCKs) are key downstream effectors of small GTPases.
• ROCK signaling is implicated in various cellular processes, including tumor development and progression.
• ROCK inhibitors are being explored as a therapeutic strategy for cancer treatment.

Purpose of the Study:

• To review recent research on ROCK inhibitors for cancer treatment.
• To summarize findings on ROCK inhibitors reported between 2015 and 2021.
• To assess the therapeutic potential of ROCK inhibitors in oncology.

Main Methods:

• Literature review of studies published from 2015 to 2021.
• Analysis of research on Rho-associated coiled-coil kinases (ROCK) inhibitors.
• Evaluation of in vitro and in vivo antitumor activities of ROCK inhibitors.

Main Results:

• Numerous ROCK inhibitors have demonstrated potent antitumor activities.
• ROCK inhibitors exhibit significant efficacy in both in vitro and in vivo cancer models.
• The reviewed studies highlight the promising therapeutic potential of these inhibitors.

Conclusions:

• ROCK inhibitors represent a promising class of drugs for cancer therapy.
• Further development of ROCK inhibitors could lead to novel cancer treatments.
• The reviewed evidence supports the continued investigation of ROCK inhibitors in oncology.